Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.
BMS posted the refund notice on the U.S. Health Resources and Services Administration (HRSA) website this week.
Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
